RNA-based therapies: A cog in the wheel of lung cancer defense.
Parvez KhanJawed Akhtar SiddiquiImayavaramban LakshmananApar Kishor GantiRavi SalgiaManeesh JainSurinder Kumar BatraMohd Wasim NasserPublished in: Molecular cancer (2021)
Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading cause of death worldwide. Despite recent advances in therapies, the overall 5-year survival rate of LC remains less than 20%. The efficacy of current therapeutic approaches is compromised by inherent or acquired drug-resistance and severe off-target effects. Therefore, the identification and development of innovative and effective therapeutic approaches are critically desired for LC. The development of RNA-mediated gene inhibition technologies was a turning point in the field of RNA biology. The critical regulatory role of different RNAs in multiple cancer pathways makes them a rich source of targets and innovative tools for developing anticancer therapies. The identification of antisense sequences, short interfering RNAs (siRNAs), microRNAs (miRNAs or miRs), anti-miRs, and mRNA-based platforms holds great promise in preclinical and early clinical evaluation against LC. In the last decade, RNA-based therapies have substantially expanded and tested in clinical trials for multiple malignancies, including LC. This article describes the current understanding of various aspects of RNA-based therapeutics, including modern platforms, modifications, and combinations with chemo-/immunotherapies that have translational potential for LC therapies.
Keyphrases
- small cell lung cancer
- simultaneous determination
- clinical trial
- nucleic acid
- mass spectrometry
- clinical evaluation
- liquid chromatography
- solid phase extraction
- radiation therapy
- gene expression
- randomized controlled trial
- small molecule
- cancer therapy
- young adults
- big data
- brain metastases
- dna methylation
- mesenchymal stem cells
- advanced non small cell lung cancer
- bioinformatics analysis
- tyrosine kinase
- free survival
- lymph node metastasis
- childhood cancer